Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

, and other important variables that are not within the control of Nektar; (vii) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (viii) the uncertain outcome of any future intellectual property, commercial or other litigation related to Nektar's proprietary product candidates, including without limitation NKTR-102; and (ix) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, filed on November 4, 2010.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise.  

(1) Parkin D, Bray F, Ferlay J, et al: Global cancer statistics, 2001. CA Cancer J Clin 55:74-108, 2005.

(2) Alvaro and Perez, Mayo Clin Proc. 2009; 84(6):533-545

Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

(650) 631-4954Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650Nektar Media Inquiries: Karen Bergman/BCC Partners

(650) 575-1509 Michelle Corral/BCC Partners

(415) 794-8662
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015  Seeger ... knee implant bellwether trial will commence October 13, 2015. ... 1995 using the 510K fast-track approval program, Zimmer NexGen ... The program only requires that companies provide evidence that ... approved product in order to gain permissions. ...
(Date:9/2/2015)... 2, 2015 Research and Markets ( ... "Medical Device Studies: Clinical Evidence (London, UK ... offering. This course has been ... gathering clinical evidence required for medical devices and ... all medical devices and the emphasis on high ...
(Date:9/2/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... Officer of Neurocrine Biosciences, will be presenting at the ... City . The live presentation takes ... PT).  The presentation will be webcast and may be ... Listeners are encouraged to visit the ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... 2 HART Health, a national manufacturer and distributor ... service division of Synergy Logistics, a Seattle-based first aid ... new franchise system. Synergy Logistics, Inc. had ... delivery service to mid-sized Seattle businesses since the early ...
... Results from studies related to ... lead developmental product candidate, fidaxomicin, will ... Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ... Exhibition Center in Boston on September 12-15, 2010. ...
Cached Medicine Technology:First Aid Supplier HART Health Acquires Competitor and Continues Expansion 2Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 3
(Date:9/2/2015)... ... September 02, 2015 , ... ... large stream of mixed documents that include EOBs, payments, and payment related documents. ... the data needed to reconcile their billing, with one efficient process and interface,“ ...
(Date:9/2/2015)... Pittsburgh, PA (PRWEB) , ... September 02, 2015 ... ... the Health Sciences clinical and academic partnership has earned international recognition as a ... rare genetic disorder that can cause sudden, catastrophic internal bleeding and stroke. ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... largest and fastest-growing interim clinical staffing companies, has completed a recapitalization with ... , BPOC and Heritage Group each offer extensive expertise and ...
(Date:9/2/2015)... Kansas City, KS (PRWEB) , ... September 02, 2015 , ... ... recently opened its newest office in Kansas – its Johnson County location. ... backgrounds in healthcare. Mike has a registered nurse background and spent over 20 years ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to be ... risk of getting ovarian cancer in her lifetime is approximately 1 in 75. This ... ovarian cancer, and 14,000 will die. , There is no test to detect ...
Breaking Medicine News(10 mins):Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3
... , , WASHINGTON, July 24 ... today in support of the minimum wage increase from $6.55 an hour ... minimum wage increase is an important step in recovering our economy, rebuilding ... it is only one of three prongs necessary to create a real ...
... common, but labeling is not required, report states , ... "enhance" uncooked meat and poultry can pose serious health ... Many fresh meat and poultry products are injected with ... not required to be listed on food labels, according ...
... , , CLEVELAND, July 24 /PRNewswire/ ... access for the uninsured and underinsured to a wide range of health ... 25 and 26, at the W.O. Walker Center, 10524 Euclid Ave. The ... provide 1100 medical, 300 vision and 200 dental patient visits. Appointments ...
... , CHICAGO, July 24 ... in designing and manufacturing portable rechargeable systems, today ... single-output power supplies. The new 350-watt series, designed ... delivers an industry-leading converter efficiency of up to ...
... WESTBROOK, Maine, July 24 IDEXX Laboratories, Inc. (Nasdaq: ... second quarter of 2009 were $265.7 million compared to $280.6 ... as defined below, was 5%. Earnings per diluted share ("EPS") ... to $0.63 for the same period in the prior year. ...
... ... Texans find affordable, direct access to medical lab testing through Any Lab Test Now®. , ... Plano, TX (PRWEB) July 24, 2009 -- This ... company has found its niche. Opened December 2008, Any Lab Test Now® in ...
Cached Medicine News:Health News:Fresh-Meat Additives May Be Dangerous for Kidney Patients 2Health News:U.S. Senator Sherrod Brown to Lend Support at MedWorks' Free Medical Clinic This Weekend 2Health News:Convection Cooled 350-Watt Open Frame Power Supply Meets Medical and Industrial Safety Standards 2Health News:IDEXX Laboratories Announces Second Quarter Results 2Health News:IDEXX Laboratories Announces Second Quarter Results 3Health News:IDEXX Laboratories Announces Second Quarter Results 4Health News:IDEXX Laboratories Announces Second Quarter Results 5Health News:IDEXX Laboratories Announces Second Quarter Results 6Health News:IDEXX Laboratories Announces Second Quarter Results 7Health News:IDEXX Laboratories Announces Second Quarter Results 8Health News:IDEXX Laboratories Announces Second Quarter Results 9Health News:IDEXX Laboratories Announces Second Quarter Results 10Health News:IDEXX Laboratories Announces Second Quarter Results 11Health News:IDEXX Laboratories Announces Second Quarter Results 12Health News:IDEXX Laboratories Announces Second Quarter Results 13Health News:IDEXX Laboratories Announces Second Quarter Results 14Health News:IDEXX Laboratories Announces Second Quarter Results 15Health News:IDEXX Laboratories Announces Second Quarter Results 16Health News:IDEXX Laboratories Announces Second Quarter Results 17Health News:IDEXX Laboratories Announces Second Quarter Results 18Health News:IDEXX Laboratories Announces Second Quarter Results 19Health News:IDEXX Laboratories Announces Second Quarter Results 20Health News:IDEXX Laboratories Announces Second Quarter Results 21Health News:IDEXX Laboratories Announces Second Quarter Results 22Health News:Cost-Conscious Texans Find Relief with Direct Access Lab Testing 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: